Accuray (ARAY) Stock Overview
Engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ARAY Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Accuray Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$2.10 |
| 52 Week Low | US$0.22 |
| Beta | 1.39 |
| 1 Month Change | -9.18% |
| 3 Month Change | -26.69% |
| 1 Year Change | -84.06% |
| 3 Year Change | -90.84% |
| 5 Year Change | -93.29% |
| Change since IPO | -99.12% |
Recent News & Updates
Recent updates
ARAY: Reset P/E Expectations And Guidance Withdrawal Will Shape Future Risk Balance
The analyst price target on Accuray has been cut by about $3.53 to reflect a lower implied fair value, a higher discount rate, and sharply reduced future P/E expectations, following recent downgrades where analysts cited softer growth and margin assumptions. Analyst Commentary Recent research on Accuray has focused on how realistic growth and margin assumptions should feed into valuation, especially after the latest downgrades and the reset in future P/E expectations.Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates
Today is shaping up negative for Accuray Incorporated ( NASDAQ:ARAY ) shareholders, with the analysts delivering a...
Future Service Contracts And Operational Transformation Will Reshape Long Term Cancer Care Access
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services used by hospitals and cancer centers worldwide. What are the underlying business or industry changes driving this perspective?The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Unfortunately for some shareholders, the Accuray Incorporated ( NASDAQ:ARAY ) share price has dived 33% in the last...Groundhog Day Once Again, As Accuray Misses And Lowers
Summary Accuray continues to disappoint with weaker revenue, weaker orders and market share, lowered guidance, and little evidence of a turnaround. ARAY's restructuring aims for $25M in annual profitability improvements, but lacks novel strategies and may risk further sales declines. Competitive pressure from Siemens Healthineers and Elekta underscores ARAY's inability to gain traction, especially in critical markets like China. Despite undervaluation, persistent cash burn and lack of turnaround visibility make the risk/reward unattractive; I plan to exit my small position. Read the full article on Seeking Alpha
Service Transformation And China Delays Will Reshape Margins Yet Eventually Support A Healthier Business
Catalysts About Accuray Accuray develops and sells radiation therapy systems and related services for cancer treatment facilities worldwide. What are the underlying business or industry changes driving this perspective?Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
The Accuray Incorporated ( NASDAQ:ARAY ) share price has fared very poorly over the last month, falling by a...Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Benign Growth For Accuray Incorporated (NASDAQ:ARAY) Underpins Its Share Price
Accuray Incorporated's ( NASDAQ:ARAY ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Returns At Accuray (NASDAQ:ARAY) Are On The Way Up
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Accuray Incorporated's (NASDAQ:ARAY) Share Price Is Matching Sentiment Around Its Revenues
With a price-to-sales (or "P/S") ratio of 0.3x Accuray Incorporated ( NASDAQ:ARAY ) may be sending very bullish signals...Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 26% Price Drop
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a horrible month, losing 26% after a relatively good period...Accuray Incorporated (NASDAQ:ARAY) Shares Fly 25% But Investors Aren't Buying For Growth
Accuray Incorporated ( NASDAQ:ARAY ) shares have had a really impressive month, gaining 25% after a shaky period...Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If'
Summary Impressive revenue growth remains elusive for Accuray despite the potential in China, and there are ongoing challenges with profitability, competition, and market scale. The last quarter's results showed mixed performance, with better than expected revenue and a small guidance boost, but overall product sales were down and the backlog shrank modestly. Sustainability remains a key issue; China is growing nicely, but revenue in Japan weakened and the company has seen its installed base in the U.S. shrink, pressuring service revenue. Accuray appears undervalued but faces significant risks; the potential for better results exists, particularly if China efforts succeed and U.S. sales stabilize, but improvement in execution has long been elusive. Read the full article on Seeking AlphaHealth Check: How Prudently Does Accuray (NASDAQ:ARAY) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Accuray Incorporated: Cheap, But With Caveats
Summary Today, we take a deeper look at Accuray Incorporated, a medical device company that manufactures radiosurgery and radiation therapy systems. Despite mid-single-digit sales growth, Accuray trades at under 50% of current revenues and is nearing profitability, but the company has a significant debt load. A couple of analyst firms believe the stock should be trading at much higher levels. An analysis around Accuray Incorporated follows in the paragraphs below. Read the full article on Seeking AlphaAccuray Remains A Perpetual 'Next Year Is Our Year' Story
Summary Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful. Execution remains critical as the company faces tough competition and needs to capitalize on growth opportunities in China and replacement/renewal opportunities in the U.S. market. Accuray shares offer potential upside, at the cost of elevated risk, if the company can overcome sales execution challenges and capitalize on emerging market opportunities. Read the full article on Seeking AlphaAccuray Incorporated's (NASDAQ:ARAY) 28% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated ( NASDAQ:ARAY ) shareholders won't be pleased to see that the share price has had a very rough...Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop
To the annoyance of some shareholders, Accuray Incorporated ( NASDAQ:ARAY ) shares are down a considerable 25% in the...Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results
It's shaping up to be a tough period for Accuray Incorporated ( NASDAQ:ARAY ), which a week ago released some...Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Accuray fair value estimate is US$2.06 Accuray's US$1.54 share...Shareholder Returns
| ARAY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.2% | -5.5% | -1.0% |
| 1Y | -84.1% | -19.0% | 14.1% |
Return vs Industry: ARAY underperformed the US Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: ARAY underperformed the US Market which returned 13.1% over the past year.
Price Volatility
| ARAY volatility | |
|---|---|
| ARAY Average Weekly Movement | 14.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ARAY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARAY's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 809 | Steve LaNeve | www.accuray.com |
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems.
Accuray Incorporated Fundamentals Summary
| ARAY fundamental statistics | |
|---|---|
| Market cap | US$29.88m |
| Earnings (TTM) | -US$49.19m |
| Revenue (TTM) | US$401.95m |
Is ARAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARAY income statement (TTM) | |
|---|---|
| Revenue | US$401.95m |
| Cost of Revenue | US$290.49m |
| Gross Profit | US$111.45m |
| Other Expenses | US$160.65m |
| Earnings | -US$49.19m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 27.73% |
| Net Profit Margin | -12.24% |
| Debt/Equity Ratio | 354.6% |
How did ARAY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 08:29 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Accuray Incorporated is covered by 16 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neil Chatterji | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |